any marketing approval, including the Biologics License Application, or 
Emergency Use Authorization; our contemplated shipping and storage plan, 
including our estimated product shelf life at various temperatures; the 
risk that demand for any products may be reduced or no longer exist; the 
ability of BioNTech to supply the quantities of BNT162 to support 
clinical development and market demand, including our production 
estimates for 2021; and challenges related to public vaccine confidence 
or awareness. Any forward-looking statements in this press release are 
based on BioNTech's current expectations and beliefs of future events, 
and are subject to a number of risks and uncertainties that could cause 
actual results to differ materially and adversely from those set forth 
in or implied by such forward-looking statements. These risks and 
uncertainties include, but are not limited to: the ability to meet the 
pre-defined endpoints in clinical trials; competition to create a 
vaccine for COVID-19; the ability to produce comparable clinical or 
other results, including our stated rate of vaccine effectiveness and 
safety and tolerability profile observed to date, in the remainder of 
the trial or in larger, more diverse populations upon commercialization; 
the ability to effectively scale our productions capabilities; and other 
potential difficulties. 
 
   For a discussion of these and other risks and uncertainties, see 
BioNTech's Annual Report on Form 20-F for the Year Ended December 31, 
2020, filed with the SEC on March 30, 2021, which is available on the 
SEC's website at www.sec.gov. All information in this press release is 
as of the date of the release, and BioNTech undertakes no duty to update 
this information unless required by law. 
 
   Pfizer Contacts: 
 
   Media Relations 
 
   Amy Rose 
 
   +1 (212) 733-7410 
 
   https://www.globenewswire.com/Tracker?data=EVe_Z1YDM11Tvi-zKlKf6JA8l-yiUEhF3KuUGHHD623gHNH00Sv5AZPOxHxcOkWAxSbPECCMh9KU_OPmcYzSXdMa3M7ULGhSYVNB65z7jjw= 
Amy.Rose@pfizer.com 
 
   Investor Relations 
 
   Chuck Triano 
 
   +1 (212) 733-3901 
 
   https://www.globenewswire.com/Tracker?data=NhcQYcSiWUDTx4IuGFQiDQWhGZhr8z6KGF6x_0YN3-DuUkFhFXO8eveAtFQJXSwceavevGYPRG5T6Jbwxq-WZBcvJl_FK37HLgBYp95gm4X9FxYGmkxftQncEcqER7aT 
Charles.E.Triano@Pfizer.com 
 
   BioNTech Contacts: 
 
   Media Relations 
 
   Jasmina Alatovic 
 
   +49 (0)6131 9084 1513 
 
   https://www.globenewswire.com/Tracker?data=LsQkIZcErTeJnjS10lcDguTslhgCRm30gwxAxETtkqN1OWhMeDGJqNFQbHDpWuUlKAA80zFNG4drQGgyghEjnCIj_0PMh0MRV_O_z797L6o= 
Media@biontech.de 
 
   Investor Relations 
 
   Sylke Maas, Ph.D. 
 
   +49 (0)6131 9084 1074 
 
   https://www.globenewswire.com/Tracker?data=fooIZcamCVgRJh2wsbCUpG0t5IqCdsjSyy8afDZlczHtF4djVcESq2W8oKchDYcBILGu_OiDoV4DpYD1Jy1ouVMB2SXTH6KBdqyrta1sX0g= 
Investors@biontech.de

(END) Dow Jones Newswires

May 07, 2021 06:45 ET (10:45 GMT)